AVRO - AVROBIO, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
37.55
+3.05 (+8.84%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close34.50
Open35.26
Bid37.50 x 200
Ask39.50 x 100
Day's Range34.27 - 38.79
52 Week Range26.51 - 38.79
Volume245,838
Avg. Volume300,619
Market Cap898.827M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-11.93
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.33
Trade prices are not sourced from all markets
  • Benzinga5 days ago

    Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls

    Avrobio Inc (NASDAQ: AVRO ), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million ...

  • GlobeNewswire24 days ago

    AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors

    AVROBIO, Inc. (AVRO), a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene therapies to treat rare diseases following a single dose, today announced the appointment of Phillip B. Donenberg to its Board of Directors. Mr. Donenberg brings more than 23 years of leadership expertise in finance, mergers and acquisitions (M&A) and operations focused in the pharmaceutical and healthcare industries.

  • GlobeNewswire26 days ago

    AVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option

    CAMBRIDGE, Mass., June 25, 2018-- AVROBIO, Inc., a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases ...

  • The Wall Street Journal28 days ago

    [$$] Five Drug Startups Reveal Plans to Join Blitz of Biotech IPOs

    Five heavily funded biotech startups could soon join the parade of drugmakers marching onto the public markets.

  • The Wall Street Journallast month

    [$$] Banner Day for Biotech as Five Drug Developers Go Public

    Five more venture-backed biotechnology companies were set to begin public trading Thursday, after each priced within or above its expected range.

  • The Wall Street Journallast month

    [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry

    Inc. went public Wednesday during what should be one of the busiest weeks for biomedical IPOs in recent memory. Nine U.S. venture-backed biotechs had their debuts in the first quarter, according to VentureSource. Enthusiasm for biotech is fueling much of the activity.

  • GlobeNewswirelast month

    AVROBIO, Inc. Announces Pricing of Initial Public Offering

    CAMBRIDGE, Mass., June 20, 2018-- AVROBIO, Inc., a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases ...

  • 8 Biotech Stocks With IPOs This Week
    InvestorPlacelast month

    8 Biotech Stocks With IPOs This Week

    This week, there are a whopping eight biotech companies going public. Biotechnology isn’t an easy sector to grasp — it takes dedication to understand investment thesis, beginning the journey from drug development and ending at the drugstore. When it comes to investing in biotech stocks, the question is not just how well is this business run but whether their products fulfill a need in a growing industry … for biotechs, this can get complicated.